INTRODUCTION

Top Abstract Introduction Materials and Methods Results Discussion References

The central nervous system (CNS) is a major target for human immunodeficiency virus type 1 (HIV-1) infection. HIV-1 enters the CNS early after systemic infection and persists there for life (20, 26, 30). About 30% of AIDS patients develop prominent cognitive, motor, and behavioral manifestations known as HIV-1 encephalopathy, AIDS dementia complex, or HIV-associated dementia (45, 48, 49, 60). HIV-1 is considered the principal etiologic agent of this disorder (22, 39, 45), but the mechanism of HIV-1-induced neuropathogenesis is unknown. The virus can be found in the brain in infiltrating macrophages, microglial cells, astrocytes, oligodendrocytes, and brain endothelial cells but only infrequently in neurons (53, 57, 67, 68, 73), indicating that the observed neuronal damage cannot be directly attributed to HIV-1 replication in these cells. Macrophages and microglial cells are considered to be the primary source of HIV-1 replication within the CNS, and HIV-1 strains isolated from the CNS generally exhibit R5 or macrophage-tropic characteristics, indicating that such strains predominate in the brain (14, 31, 34, 40, 57, 67, 68, 73). Productive infection of macrophages and microglial cells is believed to contribute to neuropathogenesis through secretion of viral (gp120, Tat, and Nef) and cellular (cytokines, chemokines, and nitric oxide) neurotoxic products (reviewed in references 35 and 41). However, HIV-1 infection of these cells may not be sufficient for the development of neuropathology. Studies in a macaque model of simian immunodeficiency virus (SIV) encephalitis indicate, for example, that there is no direct correlation between macrophage tropism and neuroinvasiveness or neurovirulence of SIV (43, 66). Recent studies have shown that neurons express CXCR4 (23, 29) and that HIV-1 strains which utilize CXCR4 for entry can induce signal transduction and apoptosis in neurons (75) specifically through these receptors (52, 75). We have shown that some primary HIV-1 isolates obtained from vitreous from AIDS patients with cytomegalovirus retinitis can infect astrocytes and T lymphocytes but not macrophages (11). Thus, multiple HIV-1 strains and brain cell types infected with the virus may contribute to HIV-1-mediated neuropathogenesis.

Recently, attention has been directed toward the potential role of astrocytes in HIV-1 neuropathogenesis (9, 19). Astrocytes are critical for brain homeostasis and for responses to pathogens and brain injury (8, 15, 19, 71), and defects in astrocyte functions may lead to neurodegeneration (54). Astrocytes also are a major target for HIV-1 infection in the brain. Depending on methodology of HIV-1 detection, stage of brain disease, and brain region analyzed, reports have shown that anywhere from 0 to 20% of astrocytes may carry the HIV-1 genome in vivo (5, 10, 25, 51, 53, 57, 67, 68), with larger-scale surveys indicating a frequency of up to 1% (67). Considering that the number of astrocytes in the brain ranges between 4 × 10¹¹ and 2 × 10¹² cells (55), the total number of HIV-1-infected astrocytes in vivo may be substantial.

We are interested in the course of HIV-1 infection of astrocytes and potential effects of that infection on astrocyte function. In contrast to productive and cytopathic infection in T cells and macrophages (reviewed in reference 39), HIV-1 infection of astrocytes is inefficient, of low productivity, and generally noncytopathic (11, 13, 21, 24, 36, 47, 65, 69, 70). We and others have estimated that only about 1% of human fetal astrocytes express virus at the peak of infection (7, 28). On this basis, there is general agreement that infection or transfection of astrocytes produces a transient burst of viral replication, which diminishes to low levels of virus expression or latency (7, 11, 56, 58, 59, 69, 70). The reasons behind this limited infection are not well understood, but they could include inefficient virus entry, intracellular restrictions to virus replication, or a combination of the two. Intracellular restrictions are suggested by findings showing that infected astrocytes contain mostly viral regulatory proteins and transcripts coding for these products but only low levels of viral structural proteins (57, 67, 69, 70). Studies indicate that this restriction may result from limited expression of HIV-1 RNA encoding the major structural proteins (69), possibly due to inefficient Rev function (42, 50). Inefficient HIV-1 production in certain glioma cell lines has also been correlated with defects in processing of HIV-1 gp160 envelope glycoprotein (58) and inefficient translation of HIV-1 structural proteins (24). Block at HIV-1 entry into astrocytes is implied by the absence of surface CD4 expression by the cells (13). In some but not all glial cell lines (17, 27), stable expression of CD4 permits high-level, productive infection by HIV-1 (59, 61, 72, 74). Transient transfection of HIV-1 DNA into astrocytes or cocultivation with HIV-1-infected cells also permits more efficient virus replication than does exposure to cell-free virus (7, 21, 47, 65, 69), and some glioma cells stably transfected with HIV-1 DNA replicate virus at high levels (21, 59). Together, these studies suggest that virus entry is a major limiting step of HIV-1 infection in astrocytes.

We reported previously that HTB148 glioma cells which were stably transfected to express surface CD4 are susceptible to efficient HIV-1 infection (72). In the present work, we applied a slightly different strategy to investigate the life cycle of HIV-1 in primary human astrocytes. Rather than confer expression of CD4 on primary astrocytes, which was technically difficult, we extended HIV-1 tropism by pseudotyping, that is, endowing native HIV-1 with heterologous envelope glycoproteins that bind commonly expressed cellular receptors. Vesicular stomatitis virus (VSV) G protein mediates entry via an endocytic pathway (44), and amphotropic murine leukemia virus (MLV) glycoprotein mediates virus-cell membrane fusion, mimicking the entry of HIV-1 (46). HIV-1 pseudotyped with either VSV or MLV envelope glycoproteins efficiently infects CD4-negative cells (2, 3, 6, 64). Here, HIV-1 NL4-3 was pseudotyped with VSV or amphotropic MLV envelopes by cotransfection of intact NL4-3 DNA and either a VSV or MLV envelope expression vector, yielding VSV/NL4-3 and MLV/NL4-3, respectively. We compared infection of primary human fetal astrocytes by native NL4-3 to infection by pseudotyped HIV-1. We found that in contrast to native NL4-3, both VSV/NL4-3 and MLV/NL4-3 were able to productively infect the majority of astrocytes, permitting quantitative analysis of the viral life cycle in these cells by Western and Northern blotting and immunofluorescent staining of cells with anti-HIV sera. Our results suggest that primary astrocytes pose no fundamental intracellular block to HIV-1 replication. These results introduce a model system of efficient HIV-1 infection of primary astrocytes for studies of the course of the HIV-1 life cycle in these cells.

	MATERIALS AND METHODS

Top Abstract Introduction Materials and Methods Results Discussion References

Cells. Fetal astrocytes were isolated from second-trimester (gestational age, 16-19 weeks) human fetal brains obtained from elective abortions in full compliance with National Institutes of Health (NIH) guidelines, as previously described (11, 75). Highly homogenous preparations of astrocytes were obtained using high-density culture conditions in the absence of growth factors in F12 Dulbecco's modified Eagle's medium (GIBCO-BRL, Gaithersburg, Md.) containing 10% fetal bovine serum, penicillin, streptomycin, and gentamicin (11, 75). Subsequently, the cells were maintained in this medium at 2 × 10⁴ to 5 × 10⁴ cells/cm² and subcultured weekly up to six times. For each experiment, a single batch of astrocytes of the same gestational age and passage was used. Cultures were regularly monitored for expression of the astrocytic marker glial fibrillary acidic protein (GFAP) and either HAM56 or CD68 to identify cells of monocyte/macrophage lineage. Only cultures that contained 99% GFAP-positive cells and rare or no detectable HAM56- or CD68-positive cells were used in our experiments (75).

HIV-1 molecular clones, envelope expression vectors, and generation of pseudotyped HIV-1. The HIV-1 molecular clones used were NL4-3, which expresses all known HIV-1 proteins (1), and NL-P1, an NL4-3 derivative carrying the marker gene human placental alkaline phosphatase (PLAP) inserted next to Nef (18). The VSV G expression vector pL-VSV-G was obtained from M. Emerman; it contains a VSV G insert in the pcDNA expression vector modified by replacing the cytomegalovirus promoter with the HIV-1 long terminal repeat (6). The amphotropic MLV envelope expression vector SV-A-MLV-Env was obtained from D. Littman; envelope expression in this vector is driven by the MLV long terminal repeat (38). High-titer virus stocks were produced in 293T human embryonic kidney cells transfected with the respective DNA by calcium phosphate precipitation (4). To generate pseudotyped virus, 1.5 × 10⁶ 293T cells cultured in 10-cm plates were cotransfected with 10 µg of HIV-1 clone DNA and 15 µg of VSV or MLV envelope expression plasmid DNA, a ratio of DNAs found to yield the highest HIV-1 infectious titers in our hands. For native HIV-1 production, 1.5 × 10⁶ 293T cells were transfected with 15 µg of NL4-3 or NL-P1 DNA. 293T culture supernatants were harvested 72 h after transfection, filtered through a 0.45-µm-pore-size Millipore filter, and stored at 80°C until use. Cell-free viral stock was tested for HIV-1 p24 core antigen content by enzyme-linked immunosorbent assay (ELISA) using the HIV-1 Ag kit as specified by the manufacturer (Coulter, Hialeah, Fla) and for titers of infectious virus by multinuclear activation of a -galactosidase indicator (MAGI) assay (33). Culture supernatants contained 1 to 2 µg of viral p24 protein per ml and 1 × 10⁶ to 2 × 10⁶ infectious units (IU) per ml. In our hands, a multiplicity of infection of 1 for CD4-positive T cells is equivalent to approximately 1 pg of viral p24 per cell (21, 59).

Cell infection and analysis of HIV-1 expression by p24 ELISA and IF. Confluent cultures of human fetal astrocytes were infected with native or pseudotyped HIV-1 at 1 pg of p24 per cell overnight and washed five times with Hanks balanced salt solution (GIBCO-BRL) before being returned to culture. At the indicated times after infection, culture supernatants were tested for the levels of HIV-1 p24 antigen by p24 ELISA and cells were removed, spotted on glass slides, fixed in acetone, and stained with AIDS patient serum to detect HIV-1 antigens by indirect immunofluorescence (IF). Astrocytes infected with NL-P1 virus were also stained for PLAP by IF using mouse anti-alkaline phosphatase antibody (Serotec, Raleigh, N.C.). GFAP-positive astrocytes were detected by IF staining using rabbit anti-GFAP (DAKO Corp., Carpinteria, Calif.). All secondary antibodies were conjugated with fluorescein isothiocyanate, positive cells were visualized under an Olympus BH-2 fluorescence microscope, and at least 200 cells were counted. HIV-1 antigen and GFAP staining were also performed on cells cultured on coverslips, plated, and infected under the same conditions as in large-scale cultures. The results were similar to those obtained with cells removed by trypsinization from large-scale cultures.

HIV-1 protein analysis by immunoblotting. Cells were counted and lysed in a buffer containing 1% Triton X-100, 0.1% sodium dodecyl sulfate (SDS), 1% sodium deoxycholate, 5 mM iodoacetamide, and 0.2 U of phenylmethylsulfonyl fluoride per ml, and cell lysates corresponding to equivalent numbers of cells were resolved by SDS-polyacrylamide gel electrophoresis on 4 to 15% polyacrylamide ready gels (Bio-Rad, Hercules, Calif.) and transferred onto a 0.2-µm-pore-size Trans-Blot nitrocellulose membrane (Bio-Rad). The membranes were incubated in 5% (wt/vol) skim milk in T-PBS (0.1% polyoxyethyline-sorbitan monolaurate in phosphate-buffered saline [PBS]) and then stained with indicated primary antibodies followed by horseradish peroxidase-conjugated second antibody. Protein bands were visualized on X-ray film after a luminescence reaction using the ECL kit (Amersham, Arlington Heights, IU.). Samples were standardized by their -tubulin content prior to final evaluations.

Viral RNA analysis by Northern blot hybridization. Total cellular RNA was isolated with TRIzol (GIBCO-BRL) as specified by the manufacturer, samples were standardized by their optical density at 262 nm, and 20 µg of RNA per lane was resolved by electrophoresis through an agarose-formaldehyde gel (1% agarose, 2.2 M formaldehyde, 10% [vol/vol] 10× MOPS [0.4 M MOPS, pH7; 0.1 M sodium acetate, 0.01 M EDTA]) in 1× MOPS (morpholinepropanesulfonic acid) running buffer using a standard procedure (4). The gels were denatured in 0.05 M NaOH-1.5 M NaCl for 30 min, neutralized in 0.5 M Tris-Cl (pH7.4) to 1.5M NaCl for 20 min, and washed in 20× SSC (1× SSC in 0.15 M NaCl plus 0.015 M sodium citrate) for 45 min, and RNA was blotted onto a 0.45-µm-pore-size NYTRAN SPC membrane (Schleicher & Schuell, Keene, N.H.) and hybridized with an 8.9-kb SacI proviral DNA fragment derived from NL4-3 (58) labeled with [-³²P]dCTP using the RadPrime DNA Labeling System (GIBCO-BRL). Hybridization was carried out overnight at 42°C in a buffer containing 6× SSC, 5× Denhardt's reagent, 0.5% SDS, 100 µg of salmon sperm DNA per ml, and 50% formaldehyde; the membranes were then washed under stringent conditions and analyzed by autoradiography.

Other analytical procedures and reagents. Cell viability was determined by trypan blue exclusion counting. The biological activity of progeny virus made in astrocytes was determined by testing virus infectivity in the MAGI assay (33). The following reagents used were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, NIH: hybridoma cells producing monoclonal anti-Gag HIV-1 p24 (obtained from Bruce Chesebro and Hardy Chen) (183-H12-5C; 1513) (14), mouse monoclonal anti HIV-1 V3 (obtained from Jon Laman) (IIIB-V3-13; 1727) (37), and monoclonal anti-Nef antiserum (obtained from Ronald Swanstrom) (HIV-1 Nef antiserum; 2949) (62). The monoclonal -tubulin antibody was purchased from Sigma (St. Louis, Mo.).

	RESULTS

Top Abstract Introduction Materials and Methods Results Discussion References

HIV-1 pseudotyped with VSV-G or MLV envelope causes lasting and highly productive infection in primary astrocytes. Infection of primary human astrocytes with native HIV-1 in vitro is inefficient, with fewer than 1% of cells expressing viral antigens and virus production being low (7, 28, 70). We first tested whether exposure of astrocytes to HIV-1 pseudotyped with VSV G or MLV envelope, which bypasses the natural mode of HIV-1 entry into these cells, can increase the susceptibility of astrocytes to HIV-1 infection and replication. Astrocytes were isolated from second-trimester human fetal brains and cultured under conditions that minimize the growth of nonastrocytic brain cells, as previously described (7, 11, 75). The cultures were regularly evaluated by IF staining for expression of GFAP, an astrocytic marker, and HAM56 or CD68, to detect macrophages and microglial cells. Cells found to contain 99% GFAP-positive cells and no detectable HAM56 and CD68 signals were used in further experiments. Staining of a representative culture for GFAP is shown in Fig. 1A. Astrocytes were exposed overnight to native NL4-3 or NL4-3 pseudotyped with MLV (MLV/NL4-3) or VSV-G (VSV/NL4-3) envelope glycoproteins at 1 pg of viral p24 per cell and tested at the indicated time intervals for expression of cell-associated HIV-1 antigens by IF staining (Fig. 1C and D) and for levels of viral p24 in culture supernatants by p24 ELISA (Fig. 2A). In parallel, cultures were monitored for cell growth kinetics and viability (Fig. 2B). As determined by IF staining, expression of cell-associated HIV-1 antigens peaked on day 7, with 68 and 34% of cells positive after VSV/NL4-3 and MLV/NL4-3 infection, respectively (Fig. 2A). Subsequently, virus expression declined at a similar rate in both VSV/NL4-3- and MLV/NL4-3-infected cultures, but, remarkably, viral proteins were still detected by IF in 8 to 9% of cells 7 weeks after infection (Fig. 2A). Figures 1C and D show examples of IF staining of HIV-1-infected astrocytes from this experiment. Consistent with IF results, parallel measurements of HIV-1 p24 antigen levels in culture supernatants revealed a peak of p24 production on day 7 at 1.7 µg of p24/ml for VSV/NL4-3-infected and 0.48 µg of p24/ml for MLV/NL4-3-infected astrocytes, followed by a gradual decline to approximately 100 ng/ml by 7 weeks after infection (Fig. 2A). As measured by IF staining and p24 antigen production, infection of astrocytes with VSV/NL4-3 was more efficient than infection with MLV/NL4-3 at the same dose (Fig. 2). The reasons for this difference are not clear, but similar results were noted in studies using other target cells (3). Infection of astrocytes with pseudotyped HIV-1 was virus dose dependent in a linear fashion as measured by IF and p24 antigen production (data not shown). In contrast to astrocytes infected with pseudotyped HIV-1 and consistent with previous studies (7, 70), only limited infection was observed in cells exposed to native NL4-3, with few astrocytes staining positive for HIV-1 antigens by IF and less than 400 pg of p24/ml being detectable in culture supernatants at the peak of infection (Fig. 2A). Similar results were obtained in more than 20 experiments using different batches of astrocytes and HIV-1. We conclude that use of HIV-1 pseudotyped with viral envelopes of a broad cellular tropism permits a rapid, highly productive, and long-lasting infection of the majority of astrocytes in culture.

View larger version (115K): [in this window] [in a new window]   FIG. 1.   GFAP expression by human fetal astrocytes and IF detection of HIV-1 antigens in infected astrocytes. (A and B) Uninfected human fetal astrocytes (16 weeks of gestational age, third passage) were grown on glass chamber slides and stained with anti-GFAP antibody (A) or irrelevant control antibody (B). (C to E) VSV/NL4-3-infected astrocytes from the experiment described in the legend to Fig. 2 were harvested, fixed, and stained for HIV-1 antigens by IF 7 days (C) and 28 days (D) after infection; cells harvested 7 days after infection, stained with an irrelevant serum, are also shown (E). Photographs were taken using an Olympus BH-2 fluorescence microscope. Magnification, ×100.

View larger version (71K): [in this window] [in a new window]   FIG. 2.   Expression of HIV-1 antigens, viability, and growth kinetics in fetal astrocytes infected with native and pseudotyped HIV-1. (A) Astrocyte cultures were infected with VSV/NL4-3, MLV/NL4-3, or NL4-3 as indicated and monitored for HIV-1-specific antigens expression by IF staining with AIDS sera and fluorescein isothiocyarate-conjugated second antibody (left panel) or by production of p24 in cell supernatants (right panel). The proportion of IF-positive cells was determined by counting at least 200 cells each in three different fields under ×20 magnification, using an Olympus BH-2 fluorescence microscope. (B) At the indicated times after infection, total cell numbers and total viable-cell numbers per system (×1,000) were determined as described in Materials and Methods.

Astrocytes infected with pseudotyped HIV-1 efficiently transcribe viral mRNA and persistently express viral structural proteins. Previous studies of HIV-1 expression in primary astrocytes and glioma cell lines produced conflicting results, with some authors suggesting restricted expression of viral RNA or proteins (24, 50, 69) and others showing no intrinsic intracellular restrictions to efficient viral replication (7, 58, 74). Efficient infection of astrocytes with pseudotyped HIV-1 (Fig. 1 and 2) permitted us to evaluate HIV-1 RNA transcription and protein expression in these cells by standard biochemical techniques of Northern blot hybridization and immunoblotting, respectively (see Fig. 3 and 4). To determine the steady-state levels of the major HIV-1 mRNA species relative to each other at different times after infection, astrocytes were infected with VSV/NL4-3, MLV/NL4-3, or NL4-3 as described above and total cellular RNA was isolated and subjected to Northern blot analysis with an HIV-1-specific probe on days 2, 14, and 28 after infection (Fig. 3). As expected because of low virus production, viral RNA was undetectable by this method in astrocytes infected with native NL4-3 (Fig. 3). In contrast, the three major HIV-1 mRNA species of 9, 4, and 2 kb were clearly detectable in astrocytes productively infected with VSV/NL4-3 or MLV/NL4-3 at all the time points tested, including 4 weeks after infection (Fig. 3). The 9-kb RNA was a predominant viral RNA species 2 and 14 days after infection and was present at about a 1:1 ratio with respect to the 4-kb HIV-1 RNA at 4 weeks after infection (Fig. 3). The 2-kb viral RNA was the least abundant species at all three time points. The consistent presence of 9-kb viral RNA in pseudotyped HIV-1-infected astrocytes correlated well with efficient virus production over the same period, as indicated by p24 levels in culture supernatants (Fig. 2). T cells productively infected by HIV-1 and tested as positive control also contained the three major HIV-1 RNA species (Fig. 3). Similar results were obtained in three independent experiments. We conclude that in our model system of HIV-1 infection of primary astrocytes, there is no selective defect in steady-state expression of the 9- and 4-kb HIV-1 mRNA or, conversely, that the 2-kb viral mRNA does not predominate over the course of infection.

View larger version (49K): [in this window] [in a new window]   FIG. 3.   Northern blot analysis of HIV-1 RNA expression in astrocytes infected with pseudotyped HIV-1. Astrocytes were infected with VSV/NL4-3, MLV/NL4-3, or NL4-3 and analyzed for HIV-1 RNA by Northern blotting 2, 14, and 28 days after infection as described in Materials and Methods. A total of 20 µg of total-cell RNA was loaded per lane. Samples from day 2 and 14 were exposed for 24 h, and samples from day 28 were exposed for 14 days. NL4-3-infected H9 cells were analyzed in parallel as positive controls; the samples were exposed for 24 h.

View larger version (38K): [in this window] [in a new window]   FIG. 4.   Western blot analysis of Gag, gp120, and Nef proteins by infected astrocytes. Astrocytes were infected with HIV-1 as indicated and tested for HIV-1 proteins by immunoblotting as described in Materials and Methods. All systems were normalized first by measurement of the -tubulin content. (A and D) Gag levels 7 and 35 days after infection, respectively. (B and C) gp120 and Nef protein levels 7 days after infection. Panel D contains four times more protein per lane than does panel A. Mock indicates uninfected astrocytes, and infected and uninfected PBL are shown for comparison. The results are representative of three experiments.

View larger version (46K): [in this window] [in a new window]   FIG. 5.   Expression of HIV-1 PLAP marker after pseudotyped HIV-1 infection. Astrocytes were infected with MLV/NL-P1 and evaluated at the indicated times by IF staining with AIDS sera or anti-PLAP antibody as described in Materials and Methods. Each time point represents counts of 200 cells each in three different fields.

Astrocytes infected with pseudotyped HIV-1 produce infectious virus. To determine whether progeny virions made by astrocytes infected with pseudotyped HIV-1 are infectious, supernatants were collected on days 14 and 21 after VSV/NL4-3 or MLV/NL4-3 infection of astrocytes, standardized for p24 content, and were subjected to titer determination for infectious HIV-1 by the MAGI assay (Fig. 6). Progeny virions collected at both time points had 6 to 10 IU per 100 pg of p24 of culture supernatant (Fig. 6). Thus, astrocytes producing HIV-1 can serve as a source of infectious progeny virus.

View larger version (78K): [in this window] [in a new window]   FIG. 6.   HIV-1-infected astrocytes produce infectious progeny virus. Astrocytes were infected with VSV/NL4-3 or MLV/NL4-3 as described in the text, and culture supernatants were collected 14 and 21 days after infection, filtered through 0.45-µm-pore-size filters, and tested for the presence of infectious virus in the MAGI assay. Values represent means and standard deviations from three different experiments.

	DISCUSSION

Top Abstract Introduction Materials and Methods Results Discussion References

Astrocytes are infected by HIV-1 in vivo (57, 67, 68), and it has been important to devise experimental systems to investigate the course and consequences of their infection. Using HIV-1 capable of entry into such CD4-negative cells through pseudotyping with VSV or MLV envelope proteins, we have found that primary human fetal astrocytes are permissive to highly productive HIV-1 infection. At the peak of infection, up to 70% of astrocytes expressed HIV-1 antigens and viral p24 production reached 1.7 µg/ml of culture supernatant (Fig. 1 and 2). Virus expression then gradually declined, but 5 to 10% of the cells still expressed virus antigens and secreted viral p24 at 0.1 µg/ml 7 weeks after infection, indicating persistent infection in a substantial minority of cells. As observed in many previous studies of astrocytes and other CD4-negative cells (7, 69), infection by native NL4-3 was 3 orders of magnitude less productive (Fig. 2). Similar to productively infected T cells (32), pseudotyped HIV-1-infected astrocytes expressed the major HIV-1 RNA species at equivalent levels, synthesized viral structural and regulatory proteins, and released infectious progeny virions. We conclude that the primary restriction to HIV-1 infection of astrocytes is at virus entry and that once this block is surmounted, astrocytes replicate HIV-1 efficiently for weeks before downregulating virus expression.

Transfection of viral DNA has been a method of choice to circumvent inefficient HIV-1 entry into primary astrocytes. Using this method, other investigators, as well as ourselves, have shown that astrocytes can transiently express HIV-1 structural proteins (7, 21, 69). The results varied depending on the extent and period of viral production, ranging from 5 to 20 days and from 200 to 50,000 pg of viral p24 antigen per ml of culture medium (7, 69). Different methods of transfection resulting in different levels of DNA uptake may account for the ranges observed. Infection by pseudotyped HIV-1 also results in transient viral expression; however, its period is on the order of weeks and its extent is 1 to 2 orders of magnitude higher than by transfection. The form of viral DNA introduced into cells by these different approaches is likely to contribute to the differences in the extent of viral expression. Transfected HIV-1 DNA is embedded in plasmid DNA and lacks the viral proteins which mediate nuclear entry and integration, and most of it is degraded in the cytoplasm. In contrast, both VSV G protein and MLV envelope protein mediate efficient uptake of retroviral nucleocapsid into cells, initiating a conventional retroviral life cycle (2, 3, 64). Use of pseudotyped HIV-1 enabled us to investigate the basic parameters of HIV-1 infection in astrocytes. We found that viral doses comparable to a multiplicity of infection of 1 in T lymphocytes i.e., about 1 pg of p24 per cell, when pseudotyped, were sufficient for infection of 50 to 70% of astrocytes, indicating that after virus entry, T lymphocytes and astrocytes are similarly susceptible to HIV-1 replication. The susceptibility of astrocytes to productive HIV-1 infection was highly reproducible. In multiple trials using different virus stocks, cells from more than 20 donors secreted microgram levels of the structural protein p24 after infection by NL4-3 pseudotyped with VSV or MLV envelope proteins. Consistent with p24 secretion, infected astrocytes also produced infectious progeny virus, indicating that HIV-1 can complete its life cycle in astrocytes, including all posttranslational processing and assembly events. Indeed, rescue of infectious HIV-1 from astrocytes was first reported in 1987 (13). These findings raise the possibility that astrocytes in the brain which carry HIV-1 may serve as a reservoir of infectious virus.

Using efficient infection, we revisited some of the basic questions regarding HIV-1 replication in astrocytes. Given previous reports that doubly spliced transcripts were preferentially expressed in astrocytes following HIV-1 DNA transfection (69) and analogous findings of Nef but not envelope proteins in astrocytes from HIV-1-infected brains (57), one goal of this work was to investigate the relative expression of HIV-1 structural and regulatory products by infected astrocytes. Northern blot analysis of viral RNA 1 week after pseudotype HIV-1 infection of astrocytes revealed expression of the three major HIV-1 transcripts at similar levels; 2 or 3 weeks after infection, the 9-kb genomic transcript was somewhat more abundant than the singly or doubly spliced transcripts, but all three were detectable by Northern blotting. To confirm that transcripts for structural and regulatory genes were similarly expressed, exported from the nucleus, and translated by astrocytes in the present system, we evaluated HIV-1 protein production by Western blotting and IF staining. Env, Gag, and Nef were detectable by immunoblotting 1 week after infection, and Gag was also detectable 5 weeks after infection, consistent with the continued secretion of large amounts of p24 core antigen. Similar findings were obtained using IF staining of the marker protein, PLAP expressed from a doubly spliced mRNA like Nef (12, 18) or HIV-1 structural proteins. The numbers of cells expressing structural proteins or PLAP were similar, reaching a peak of about 30% of cells and declining at 7 weeks to 10 and 15%, respectively. Our findings indicate that HIV-1 infection of primary astrocytes results in a very high peak of coordinated expression of viral structural and regulatory genes followed by a decline in parallel of the major viral products over several weeks. Conversely, we have seen no evidence in our system for preferential expression of the 2-kb HIV-1 RNA and Nef protein observed in other systems (57, 69).

Another approach to investigate astrocyte susceptibility to HIV-1 infection in culture employed transformed astrocytic cell lines transiently or stably transfected with HIV-1 DNA. Several studies found specific and well-defined blocks to virus replication, including abnormal HIV-1 RNA transcription (69), block of Rev function (42, 50), or inefficient translation of some viral mRNA species (24). However, using different glioblastoma cell lines, other investigators, including ourselves, found that once appropriate receptors for virus entry were expressed, the cells were highly susceptible to HIV-1 infection (61, 72, 74). In another study, we established chronically infected U251-MG glioblastoma cell lines by transfection of HIV-1 DNA and drug selection (21). Like the system described here, these cells also downregulated HIV-1 expression over time but with a coordinated decline in viral products and no clear evidence of abnormal HIV-1 RNA transcription or translation or of blockage of Rev function (59, 72). At this point it is not clear which of these different styles of virus replication reflects the course of HIV-1 infection of astrocytes in the brain.

The consensus of many studies of brains from HIV-1-infected persons is that astrocytes carry viral DNA at frequencies approximating 1%. It is a very interesting question to ask what route of entry was used by HIV-1 to establish infection in these CD4-negative cells, but the virus seemed to be able to enter astrocytes and synthesize viral DNA. In culture, transmission of HIV-1 to astrocytes by cell contact is more efficient than exposure to cell-free virus (47), and this may play a role in the brain. A different critical question is the extent to which this HIV-1 DNA is expressed in astrocytes in the brain. The consensus is that the majority of HIV-1-infected astrocytes do not express viral RNA, at least at levels easily detected in productively infected macrophages or microglia, although there are reports of HIV-1 RNA and structural proteins in astrocytes in the brain (25, 53). We suggest that the system described here is one reasonable approach to investigate the regulation of viral DNA expression by astrocytes. We have shown that cells initially synthesize the major HIV-1 products, including infectious progeny virus, but that after a time this expression is attenuated. Our system offers the possibility of investigating the mechanism of this attenuation by ensuring that the majority of astrocytes in culture are infected, express viral products, and, later, coordinately downregulate this expression.